R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness.
It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response.
This can be done after a waiting period of one day.
As patients may not respond to R-Gene 10 (10% Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result.
A second test can be performed after a waiting period of one day.
Some patients who respond to R-Gene 10 do not respond to insulin and vice versa.The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.
There have been two reports of possible overdosage of R-Gene 10 in children.
EXTREME CAUTION MUST BE EXERCISED WHEN INFUSING R-GENE 10 INTO PEDIATRIC PATIENTS.OVERDOSAGE OF R-GENE 10 IN PEDIATRIC PATIENTS CAN RESULT IN HYPERCHLOREMIC METABOLIC ACIDOSIS, CEREBRAL EDEMA, OR POSSIBLY DEATH.R-Gene 10 should always be administered by intravenous injection because of its hypertonicity.A suitable antihistaminic drug should be available in the event that an allergic reaction occurs.R-Gene 10 is a diagnostic aid and is not intended for therapeutic use.